| P50 | author | Martin Prieto | Q57217333 |
| | Gloria Sanchez Antolin | Q75407662 |
| P2093 | author name string | Javier Salmerón | |
| | Francisco Jorquera | |
| | Esther Molina | |
| | Juan Manuel Pascasio | |
| | Manuel Rodríguez | |
| | Miguel Ángel Casado | |
| | José Luis Calleja | |
| | José Antonio Pons | |
| | José Manuel González | |
| | Javier Fuentes | |
| | María Luisa García-Buey | |
| | Enrique Fraga | |
| | María Ángeles Blanco | |
| | María Lucía Bonet | |
| | TENOSIMP-B Research Group | |
| P2860 | cites work | Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. | Q46217486 |
| | Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. | Q54599747 |
| | Management of chronic hepatitis B before and after liver transplantation | Q27024831 |
| | EASL clinical practice guidelines: Management of chronic hepatitis B virus infection | Q29615868 |
| | Interpreting trial results following use of different intention-to-treat approaches for preventing attrition bias: a meta-epidemiological study protocol. | Q34264322 |
| | Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study | Q34317204 |
| | Lamivudine for patients with chronic hepatitis B and advanced liver disease | Q34551713 |
| | Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients | Q35152367 |
| | Cost of Treatment in HBeAg-Negative Chronic Hepatitis B Patients with 10-Years Projection Analysis | Q35827531 |
| | Hepatitis B e antigen-positive chronic hepatitis B: natural history and treatment | Q36467965 |
| | Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment | Q36467970 |
| | Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study. | Q39014096 |
| | Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. | Q39014100 |
| | Concurrent and predictive validity of a self-reported measure of medication adherence | Q39512844 |
| | In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants | Q40157026 |
| | Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. | Q40245240 |
| | Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus | Q40262602 |
| | Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. | Q41175515 |
| | Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial. | Q41538789 |
| | Effect of nucleoside and nucleotide analogues on renal function in patients with chronic hepatitis B virus monoinfection. | Q41626780 |
| | Tenofovir monotherapy after achieving complete viral suppression on entecavir plus tenofovir combination therapy | Q42145398 |
| | No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. | Q42277100 |
| | Evolving residency requirements for ambulatory care training for five medical specialties, 1961 to 1989. | Q42580515 |
| | Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. | Q42989166 |
| | Drug therapy: tenofovir | Q42992858 |
| | Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues | Q43226767 |
| | Consensus document of the Spanish Association for the Study of the Liver on the treatment of hepatitis B infection (2012) | Q44531434 |
| | Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. | Q44709445 |
| | Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. | Q45023133 |
| | Chronic hepatitis B--new goals, new treatment. | Q46217480 |
| P433 | issue | 41 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | tenofovir | Q155954 |
| | lamivudine | Q422631 |
| | chronic hepatitis B | Q55779876 |
| P304 | page(s) | 7459-7469 | |
| P577 | publication date | 2017-11-01 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study | |
| P478 | volume | 23 | |